Study on PG-116800 for Knee Osteoarthritis
Author Information
Author(s): Piotr Krzeski, Chris Buckland-Wright, Géza Bálint, Gary A Cline, Karen Stoner, Robert Lyon, John Beary, William S Aronstein, Tim D Spector
Primary Institution: Procter & Gamble Pharmaceuticals
Hypothesis
Does PG-116800, a matrix metalloproteinase inhibitor, effectively reduce symptoms and slow the progression of knee osteoarthritis?
Conclusion
The study found that PG-116800 did not show efficacy in treating knee osteoarthritis and was associated with significant musculoskeletal side effects.
Supporting Evidence
- PG-116800 did not slow the progression of joint space narrowing compared to placebo.
- 35% of patients reported arthralgia as an adverse effect.
- 23% of patients had a significant decrease in shoulder range of motion.
- The 200 mg dose was discontinued due to increased adverse effects.
- Musculoskeletal side effects were similar to those reported for other MMP inhibitors.
Takeaway
This study tested a new drug for knee pain but found it didn't help and caused some side effects.
Methodology
A randomized, double-blind, placebo-controlled study with 401 patients over 12 months, measuring joint space narrowing and symptoms.
Potential Biases
Potential bias due to the unblinding of the highest dose group and the subjective nature of some reported symptoms.
Limitations
The study was limited by the high dropout rate in the 200 mg group and the inability to differentiate drug-related symptoms from osteoarthritis symptoms.
Participant Demographics
The majority of participants were postmenopausal females aged 40 to 80 with mild to moderate knee osteoarthritis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website